



PRESS RELEASE

Uppsala, Sweden, August 30, 2006

Resistentia reports pioneering results from phase I allergy immunotherapy trial

The interim report from Resistentia's phase I trial with RP01, a novel universal allergy immunotherapy, shows positive results. The therapy was well tolerated and the healthy volunteers developed anti-IgE antibodies, supporting the novel mode of action of the immunotherapy.

"There is a tremendous need for an efficient, long-acting and cost-effective asthma and allergy treatment. The strength of the interim report has encouraged us to step up our development efforts ahead of the upcoming phase II trials," says Marcus Bosson, CEO of Resistentia Pharmaceuticals. He adds: "We can see that this immunotherapy produces the desired effect. This is an important milestone in the development process".

RP01 induces the immune system to produce antibodies against Immunoglobulin E (IgE), the key molecule triggering allergic reactions. The antibodies induced by the immunotherapy bind to IgE and block it from starting allergic reactions. The treatment thus has the potential to block allergenic triggers such as grass, pollen or dust mite.

The main purpose of the trial was to study the safety and tolerability of the immunotherapy. Interim data indicate no changes in the studied safety parameters. Those participating in the study have not displayed any general adverse effects that can be linked to the treatment.

A secondary objective of the study was to establish the pharmacodynamic profile of the immunotherapy. Here as well, interim data displayed positive results with development of anti-IgE antibodies.

The phase I clinical trial, which was initiated in March 2006, includes several groups of healthy volunteers that have been given escalating doses of the immunotherapy.

Professor Sven-Erik Dahlén, Chairman of Resistentia's Scientific Advisory Board, concludes: "The mechanism developed in discovery research has now been confirmed in man with no apparent safety concerns. It will be very interesting to follow the continued clinical development in subjects with allergy and asthma".

Resistentia

Resistentia Pharmaceuticals AB
Visiting address: Kungsängsvägen 25
Box 853, SE-751 08 Uppsala
Sweden

Tel: +46 (0)18 65 39 00
Fax: +46 (0)18 65 39 10
Internet: www.resistentia.se
VATno. SE556554158701



Preparations for phase II clinical trials in allergic patients continue.

For further information, please contact:

Marcus Bosson, CEO

+46 18 65 39 01, +46 70 693 82 81 or marcus.bosson@resistentia.se

Vidar Wendel-Hansen, Senior Vice President Clinical Development

+46 18 65 39 25, +46 70 326 10 32 or vidar.wendel-hansen@resistentia.se

About Resistentia Pharmaceuticals

Resistentia Pharmaceuticals AB is a privately held biotech company developing innovative immunotherapies that target allergy and asthma as well as inflammatory disorders. Founded in 1998, the company has developed an industrial organization with experiences ranging from molecular immunology, pre-clinical and clinical drug development to industrial biopharmaceutical production. In addition to its lead anti-IgE immunotherapeutic, Resistentia has initiated pre-clinical development of an immunotherapeutic against complement factor C5a for the treatment of rheumatoid arthritis and other autoimmune diseases.

About RP01

RP01 is an immunotherapeutic that stimulates the immune system to produce antibodies against IgE (Immunoglobulin E), the key mediator of allergic reactions. The antibodies bind to IgE, thereby blocking it from causing allergic reactions. Such a mechanism of action is efficient regardless of what triggers the allergy, be it pollen, grass, dust mite, foodstuffs or pets.

RP01 has been investigated in a series of pre-clinical studies and has displayed strong efficacy in combination with an excellent safety profile. RP01 will primarily target allergic asthma. Other potential indications include allergic rhinitis and peanut allergy.

Resistentia

Resistentia Pharmaceuticals AB
Visiting address: Kungsängsvägen 25
Box 853, SE-751 08 Uppsala
Sweden

Tel: +46 (0)18 65 39 00
Fax: +46 (0)18 65 39 10
Internet: www.resistentia.se
VATno. SE556554158701